Amylyx Pharmaceuticals, Inc.
AMLX
$3.63
-$0.045-1.23%
| Weiss Ratings | AMLX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E+ | |||
| Rating Factors | AMLX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | AMLX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.52 | |||
| Price History | AMLX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 7.89% | |||
| 30-Day Total Return | 3.28% | |||
| 60-Day Total Return | -12.01% | |||
| 90-Day Total Return | -32.87% | |||
| Year to Date Total Return | -7.29% | |||
| 1-Year Total Return | 14.35% | |||
| 2-Year Total Return | -89.37% | |||
| 3-Year Total Return | -85.41% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -49.52% | |||
| 52-Week Low % Change | 133.02% | |||
| Price | AMLX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $7.27 | |||
| 52-Week Low Price | $1.58 | |||
| 52-Week Low Price (Date) | Jun 17, 2024 | |||
| 52-Week High Price (Date) | Nov 08, 2024 | |||
| Valuation | AMLX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 325.17M | |||
| Enterprise Value | 150.65M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -4.44 | |||
| Earnings Per Share Growth | -734.56% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 2.88 | |||
| Price/Book (Q) | 1.53 | |||
| Enterprise Value/Revenue (TTM) | 1.72 | |||
| Price | $3.63 | |||
| Enterprise Value/EBITDA (TTM) | -0.48 | |||
| Enterprise Value/EBIT | -0.48 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | AMLX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 68.59M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | AMLX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 617 682 0917 | |||
| Address | 43 Thorndike Street Cambridge, MA 02141 | |||
| Website | amylyx.com | |||
| Country | United States | |||
| Year Founded | 2013 | |||
| Profitability | AMLX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -360.22% | |||
| Profit Margin | -345.35% | |||
| Management Effectiveness | AMLX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -55.33% | |||
| Return on Equity | -- | |||
| Income Statement | AMLX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 87.37M | |||
| Total Revenue (TTM) | 87.37M | |||
| Revenue Per Share | $1.27 | |||
| Gross Profit (TTM) | -141.35M | |||
| EBITDA (TTM) | -313.83M | |||
| EBIT (TTM) | -314.73M | |||
| Net Income (TTM) | -301.74M | |||
| Net Income Avl. to Common (TTM) | -301.74M | |||
| Total Revenue Growth (Q YOY) | -100.61% | |||
| Earnings Growth (Q YOY) | -893.62% | |||
| EPS Diluted (TTM) | -4.44 | |||
| EPS Diluted Growth (Q YOY) | -888.76% | |||
| Balance Sheet | AMLX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 176.50M | |||
| Cash Per Share (Q) | $2.57 | |||
| Total Current Assets (Q) | 189.43M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 164.77M | |||
| Current Ratio (Q) | 6.669 | |||
| Book Value Per Share (Q) | $2.40 | |||
| Total Assets (Q) | 193.63M | |||
| Total Current Liabilities (Q) | 28.41M | |||
| Total Debt (Q) | 1.98M | |||
| Total Liabilities (Q) | 28.87M | |||
| Total Common Equity (Q) | 164.77M | |||
| Cash Flow | AMLX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 75.65M | |||
| Cash from Financing (TTM) | 348.00K | |||
| Net Change in Cash (TTM) | -92.08M | |||
| Levered Free Cash Flow (TTM) | -171.65M | |||
| Cash from Operations (TTM) | -167.65M | |||
